In a recent phase I and II clinical trial (NCT03389035), we examined the treatment feasibility of BCP-ALL patients who relapsed after alloHSCT with donor-derived anti-CD19 CAR-T cells (CARCIK-CD19) engineered with the sleeping beauty (SB) transposon. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.